½ÃÀ庸°í¼­
»óǰÄÚµå
1813307

¼¼°èÀÇ ³²¼º »ý½Ä ´É·Â ÃßÀû ½ÃÀå : ¿¹Ãø - Á¦Ç°º°, ÀÌ¿ë »ç·Êº°, À¯Åë ä³Îº°, ±â¼úº°, ÃÖÁ¾ »ç¿ëÀÚº°, Áö¿ªº° ºÐ¼®(-2032³â)

Male Fertility Tracking Market Forecasts to 2032 - Global Analysis By Product, Use Case, Distribution Channel, Technology, End User and By Geography

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Stratistics Market Research Consulting | ÆäÀÌÁö Á¤º¸: ¿µ¹® 200+ Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    



¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

Stratistics MRC¿¡ µû¸£¸é ¼¼°èÀÇ ³²¼º »ý½Ä ´É·Â ÃßÀû ½ÃÀåÀº 2025³â¿¡ 44¾ï 8,000¸¸ ´Þ·¯·Î ÃßÁ¤µÇ°í, ¿¹Ãø ±â°£ µ¿¾È CAGR 6.51%·Î ¼ºÀåÇÒ Àü¸ÁÀ̸ç, 2032³â¿¡´Â 69¾ï 7,000¸¸ ´Þ·¯¿¡ À̸¦ Àü¸ÁÀÔ´Ï´Ù.

³²¼º »ý½Ä ´É·Â ÃßÀûÀº ³²¼º »ý½Ä ´É·Â¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ´Ù¾çÇÑ »ý¹°ÇÐÀû, ¶óÀÌÇÁ½ºÅ¸ÀÏ ¹× °Ç°­ ¿äÀÎÀ» ¸ð´ÏÅ͸µÇÏ°í ºÐ¼®ÇÏ´Â °úÁ¤À» ¸»ÇÕ´Ï´Ù. Á¤ÀÚ ¼ö, ¿îµ¿·ü, ÇüÅÂ, Å×½ºÅ佺Å×·Ð °ª, À½³¶ ¿Âµµ, ´ÙÀÌ¾îÆ®, ¿îµ¿, ¼ö¸é, ½ºÆ®·¹½º °ü¸®¿Í °°Àº »ýȰ ½À°ü°ú °°Àº ¸Å°³ º¯¼ö¸¦ ÃßÀûÇÏ´Â °ÍÀ» Æ÷ÇÔÇÕ´Ï´Ù. °í±Þ µðÁöÅÐ Åø, ¿þ¾î·¯ºí, ¸ð¹ÙÀÏ ¾ÖÇø®ÄÉÀ̼ÇÀº ½Ç½Ã°£ ÀλçÀÌÆ® ¹× ¿¹Ãø ºÐ¼®À» Á¦°øÇϱâ À§ÇØ Á¡Á¡ ´õ ¸¹ÀÌ »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. ÀÓ½ÅÀÇ ÆÐÅÏ, ÀáÀçÀûÀÎ ¹®Á¦, Àӽſ¡ ÃÖÀûÀÇ Å¸À̹ÖÀ» È®ÀÎÇÔÀ¸·Î½á ³²¼º »ý½Ä ´É·Â ÃßÀûÀº ÀӽЏñÇ¥¸¦ ´Þ¼ºÇÏ´Â Ä¿ÇÃÀ» Áö¿øÇÏ´Â µ¿½Ã¿¡ ³²¼ºÀÌ »ý½Ä °Ç°­À» À¯ÁöÇÏ°í ±âº» ÁúȯÀÇ Â¡Èĸ¦ Á¶±â¿¡ ¹ß°ßÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù.

³²¼º ¿äÀÎÀ¸·Î ÀÎÇÑ ºÒÀÓ À¯º´·ü »ó½Â

Á¤ÀÚ °Ç°­ »óÅÂÀÇ °¨¼Ò ¹× ÀÇ½Ä Áõ°¡´Â ´õ Á¶±â Áø´Ü¿¡ ´ëÇÑ ³ë·ÂÀ» ÃËÁøÇÕ´Ï´Ù. ¸ð¹ÙÀÏ ¾Û ¹× °¡Á¤¿ë ŰƮ¿Í °°Àº µðÁöÅÐ µµ±¸´Â ½ÇÇè½Ç ±â¹Ý °Ë»ç¸¦ ´ëüÇϱâ À§ÇØ »ç¿ëÇϱ⠽¬¿î ¿É¼ÇÀ¸·Î ºÎ»óÇϰí ÀÖ½À´Ï´Ù. AI¸¦ Ȱ¿ëÇÑ Á¤¾× ºÐ¼®Àº Áø´Ü Á¤È®µµ ¹× »ç¿ëÀÚ °æÇèÀ» Çâ»ó½Ã۰í ÀÖ½À´Ï´Ù. º¸´Ù ±¤¹üÀ§ÇÑ ºÒÀÓ Ä¡·á °æ·Î¿ÍÀÇ ÅëÇÕÀº °ü¸®ÀÇ Áö¼Ó¼ºÀ» Çâ»ó½Ãŵ´Ï´Ù. ÀÌ·¯ÇÑ Ãß¼¼´Â ½ÃÀåÀ» Àû±ØÀûÀÎ Àç»ý»ê °Ç°­À» ½ÇÇöÇÏ´Â Áß¿äÇÑ ¼ö´ÜÀ¸·Î »ï°í ÀÖ½À´Ï´Ù.

ÀÓ»ó ȸÀÇ·Ð ¹× Áø·á °æ·Î¿ÍÀÇ Á¦ÇÑÀû ÅëÇÕ

Á¤È®¼º ¹× Ç¥ÁØÈ­¿¡ ´ëÇÑ ¿ì·Á°¡ ÀÇ»çÀÇ Áö¿øÀ» ¹æÇØÇÕ´Ï´Ù. ÀüÀÚ ÀÇ·á ½Ã½ºÅÛ°úÀÇ È£È¯¼º ºÎÁ·Àº ÀÓ»óÀû À¯¿ë¼ºÀ» °¨¼Ò½Ãŵ´Ï´Ù. ÆÀ¿öÅ©°¡ ºÎÁ·ÇÑ ÄÉ¾î ÆÐ½º¿þÀÌ´Â ÃßÀû°ú Ä¡·áÀÇ °áÇÕÀ» ¾àÈ­½Ãŵ´Ï´Ù. µðÁöÅÐ Çï½ºÅøÀ» µÑ·¯½Ñ ±ÔÁ¦ÀÇ ºÒÈ®½Ç¼ºÀÌ ÀÇ·á±â°ü¿¡ ´ëÇÑ µµÀÔÀ» ´ÊÃß°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¹®Á¦´Â ÀÓ»ó °³¹ßÀ» °è¼Ó Á¦ÇÑÇϰí ÀÖ½À´Ï´Ù.

»çȸÀû ÀÎÁö Çâ»ó ¹× ½ºÆ¼±×¸¶ ¿ÏÈ­

±³À° ÀÌ´Ï¼ÅÆ¼ºê ¹× ¹Ìµð¾î º¸µµ´Â Àç»ý»ê °Ç°­À» µÑ·¯½Ñ °³¹æÀûÀÎ ´ëÈ­¸¦ ÃËÁøÇÕ´Ï´Ù. ÀþÀº »ç¿ëÀÚ´Â µðÁöÅÐ À£ºù µµ±¸¸¦ ´õ ¼ö¿ëÇϱ⠽±½À´Ï´Ù. Å×Å© ±â¾÷ ¹× ÀÇ·á ¼­ºñ½º Á¦°ø¾÷üÀÇ Çù¾÷Àº ½Å·Ú¼º°ú µµ´Þ¹üÀ§¸¦ ³ôÀÔ´Ï´Ù. ¼Ò¼È Ç÷§ÆûÀº Áö¸íµµ¿Í Âü¿©µµ¸¦ ³ôÀ̰í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ º¯È­°¡ ½ÃÀå È®´ëÀÇ ±â¼¼¸¦ âÃâÇϰí ÀÖ½À´Ï´Ù.

¼¼ºÐÈ­µÈ »óȯ ¹× Àڱ⠺δã¾×

Áø´Ü ŰƮ¿Í µðÁöÅÐ Ç÷§ÆûÀº Á¾Á¾ Ç¥ÁØ ÀÇ·á ÇýÅÿ¡¼­ Á¦¿ÜµË´Ï´Ù. ºñ¿ë¿¡ ¹Î°¨ÇÑ »ç¿ëÀÚ´Â °æÁ¦Àû ¿ì·Á·Î °Ë»ç¸¦ Áö¿¬Çϰųª ÇÇÇÒ ¼ö ÀÖ½À´Ï´Ù. ³²¼º »ý½Ä ÀÇ·á¿¡ ´ëÇÑ °øÀû ÀÚ±ÝÀº ¿©ÀüÈ÷ Á¦ÇѵǾî ÀÖ½À´Ï´Ù. »óȯ Á¤Ã¥ÀÇ Áö¿ª °ÝÂ÷°¡ ¾×¼¼½º °ÝÂ÷¸¦ ¾ÇÈ­½Ã۰í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ÀçÁ¤Àû Á¦¾àÀº Á¾ÇÕÀûÀÎ ½ÃÀå ¼ºÀåÀÇ À§ÇèÀÌ µË´Ï´Ù.

COVID-19ÀÇ ¿µÇâ :

COVID-19ÀÇ ´ëÀ¯ÇàÀº °ø±Þ¸ÁÀ» È¥¶õ½º·´°Ô Çϰí, Á¦Ç° Ãâ½Ã¸¦ Áö¿¬½ÃÄ×À¸¸ç, ´ë¸é Áø·á¸¦ Á¦ÇÑÇÔÀ¸·Î½á ³²¼º »ý½Ä ´É·Â ÃßÀû ½ÃÀå¿¡ Å« ¿µÇâÀ» ¹ÌÃÆ½À´Ï´Ù. Æó¼â Á¶Ä¡ ¹× »çȸÀû °Å¸®¸¦ µÎ´Â Á¶Ä¡·Î ºÒÀÓ Ä¡·á Ŭ¸®´Ð¿¡ ´ëÇÑ Á¢±ÙÀÌ °¨¼ÒÇÏ°í °ü·Ã ±â¼úÀÇ Ã¤ÅÃÀÌ Áö¿¬µÇ¾ú½À´Ï´Ù. ±×·¯³ª, Àç»ý»ê °Ç°­¿¡ ´ëÇÑ ÀÇ½Ä Áõ°¡¿Í µðÁöÅÐ Ç÷§Æû¿¡ ´ëÇÑ ¼±È£µµ Áõ°¡´Â ºÒÀÓ Ä¡·á ÃßÀû ¾Û°ú Ȩ ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä¸¦ ¹Ð¾î ¿Ã·È½À´Ï´Ù. ¿ø°Ý ÀÇ·á ¼­ºñ½º ¹× ¿ø°Ý ¸ð´ÏÅ͸µ µµ±¸·ÎÀÇ ÀüȯÀº ±â¼ú Çõ½ÅÀ» °¡¼ÓÈ­ÇßÀ¸¸ç, ´çÃÊ ½ÃÀå °úÁ¦¿¡µµ ºÒ±¸Çϰí Àå±âÀûÀÎ ±âȸ¸¦ ÃËÁøÇß½À´Ï´Ù.

¿¹Ãø ±â°£ µ¿¾È °¡Á¤¿ë Á¤¾× ºÐ¼® ŰƮ ºÐ¾ß°¡ ÃÖ´ë°¡ µÉ Àü¸Á

°¡Á¤¿ë Á¤¾× ºÐ¼® ŰƮ ºÐ¾ß´Â ½ÅÁßÇÏ°í »ç¿ëÇϱ⠽¬¿î Áø´Ü¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÔ¿¡ µû¶ó ¿¹Ãø ±â°£ µ¿¾È ÃÖ´ë ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ Å°Æ®´Â ÀÓ»óÀ» ¹æ¹®ÇÏÁö ¾Ê°í Á¤ÀÚ ¸Å°³ º¯¼ö¿¡ ´ëÇÑ ½Ç½Ã°£ ÀλçÀÌÆ®¸¦ Á¦°øÇÕ´Ï´Ù. ¸ð¹ÙÀÏ ¾Û°úÀÇ ÅëÇÕÀ¸·Î ÃßÀû ¹× Âü¿©°¡ Çâ»óµË´Ï´Ù. ÀüÀÚ»ó°Å·¡ÀÇ °¡¿ë¼ºÀº ¼ÒºñÀÚÀÇ Á¢±ÙÀ» È®´ëÇϰí ÀÖ½À´Ï´Ù. ÇÁ¶óÀ̹ö½Ã¿Í Àú·ÅÇÑ °¡°Ý¿¡ ´ëÇÑ ¼±È£µµ°¡ º¸±ÞÀ» µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù. ÀÌ ºÎ¹®Àº ³²¼º ºÒÀÓ Ä¡·á¿¡¼­ ¿ìÀ§¸¦ À¯ÁöÇÏ´Â °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

ºÒÀÓ Ä¡·á Ŭ¸®´Ð ¹× ü¿Ü¼öÁ¤(IVF) ¼¾ÅÍ ºÎ¹®Àº ¿¹Ãø ±â°£ µ¿¾È °¡Àå ³ôÀº CAGRÀ» °¡Áú °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¿¹Ãø ±â°£ µ¿¾È º¸Á¶ »ý½Ä ±â¼ú¿¡¼­ µðÁöÅÐ ÃßÀû µµ±¸ÀÇ ÅëÇÕ Áõ°¡·Î ºÒÀÓ Ä¡·á Ŭ¸®´Ð ¹× IVF ¼¾ÅÍ ºÐ¾ß°¡ °¡Àå ³ôÀº ¼ºÀå·üÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. Ä¡·á¿øÀº Ä¡·á¸¦ °³º°È­Çϰí È¿À²¼ºÀ» Çâ»ó½Ã۱â À§ÇØ ¿¬°á Áø´ÜÀ» äÅÃÇÕ´Ï´Ù. µ¥ÀÌÅÍ Áß½ÉÀÇ ºÒÀÓ Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä°¡ ½º¸¶Æ® ±â¼ú¿¡ ´ëÇÑ ÅõÀÚ¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. Àåºñ Á¦Á¶¾÷ü ¹× ÀÓ»ó ³×Æ®¿öÅ© °£ÀÇ ÆÄÆ®³Ê½ÊÀ¸·Î »óÈ£ ¿î¿ë¼ºÀÌ Çâ»óµÇ¾ú½À´Ï´Ù. ü¿Ü¼öÁ¤(IVF) ¼­ºñ½º¿Í ³²¼º ¿äÀÎ Áø´ÜÀÇ ¼ºÀåÀÌ Ã¤¿ëÀ» °¡¼ÓÈ­Çϰí ÀÖ½À´Ï´Ù. ÀÌ ºÎ¹®Àº ¼¼°è ºÒÀÓ Ä¡·á »ýŰè Àü¹Ý¿¡ °ÉÃÄ ºü¸£°Ô È®´ëµË´Ï´Ù.

ÃÖ´ë Á¡À¯À² Áö¿ª

¿¹Ãø ±â°£ µ¿¾È ºÏ¹Ì´Â »ý½Ä ÀÇ·á¿¡ ´ëÇÑ ÀÇ½Ä °íÁ¶, µðÁöÅÐ Çï½ºÅøÀÇ Ã¤¿ë È®´ë, ÷´Ü ÇコÄɾî ÀÎÇÁ¶óÀÇ Á¸Àç·Î ÀÎÇØ ÃÖ´ë ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¹Ì±¹°ú ij³ª´Ù¿Í °°Àº ±¹°¡¿¡¼­´Â °¡Á¤¿ë ºÒÀÓ Ä¡·á ŰƮ, ½º¸¶Æ®Æù ±â¹Ý ºÐ¼® Àåºñ ¹× ¿¬°á ÀåÄ¡ÀÇ ¼ö¿ëÀÌ È®´ëµÇ°í ÀÖ½À´Ï´Ù. ÁöÁöÀûÀÎ ÇコÄɾî Á¤Ã¥ ¹× ºÒÀÓ Ä¡·á Ŭ¸®´ÐÀÇ Àû±ØÀûÀÎ Âü¿©°¡ º¸±ÞÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. »ýȰ ½À°ü°ú °ü·ÃµÈ ºÒÀÓ ¹®Á¦ÀÇ ¿µÇâ°ú ¿ø°Ý ÀÇ·á Ç÷§ÆûÀÇ ³ôÀº º¸±Þ·üÀº ÀÌ Áö¿ª ½ÃÀå Àü¸ÁÀ» ´õ¿í °­È­Çϰí ÀÖ½À´Ï´Ù.

CAGRÀÌ °¡Àå ³ôÀº Áö¿ª :

¿¹Ãø ±â°£ µ¿¾È ¾Æ½Ã¾ÆÅÂÆò¾çÀº °¡Àå ³ôÀº CAGRÀ» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ¹®È­Àû º¯È­, ÇコÄÉ¾î µðÁöÅÐÈ­ÀÇ ÁøÀü, °¡Á· °èȹ¿¡ ´ëÇÑ °ü½É Áõ°¡°¡ ±× ¿äÀÎÀÌ µÇ°í ÀÖ½À´Ï´Ù. Áß±¹, Àεµ, ÀϺ», Çѱ¹, È£ÁÖ µîÀÇ ±¹°¡¿¡¼­´Â Àú·ÅÇÑ ºÒÀÓ Ä¡·á ÃßÀû ÀåÄ¡ ¹× ¸ð¹ÙÀÏ ¾ÖÇø®ÄÉÀ̼ÇÀÇ µµÀÔÀÌ È®´ëµÇ°í ÀÖ½À´Ï´Ù. ÀÌ Áö¿ªÀº ¸®ÇÁ·Î´öƼºê Çコ¸¦ Áö¿øÇÏ´Â °è¹ß Ä·ÆäÀΰú Á¤ºÎÀÇ ÀÌ´Ï¼ÅÆ¼ºê Áõ°¡°¡ Ư¡ÀÔ´Ï´Ù. ±Þ¼ÓÇÑ µµ½ÃÈ­, °¡Ã³ºÐ ¼Òµæ Áõ°¡, ½º¸¶Æ®ÆùÀÇ º¸±ÞÀÌ ½ÃÀå ¼ºÀå¿¡ Å©°Ô ±â¿©Çϰí ÀÖÀ¸¸ç, ¾Æ½Ã¾ÆÅÂÆò¾çÀº ±â¼ú Çõ½ÅÀÇ ¿ªµ¿ÀûÀÎ °ÅÁ¡ÀÌ µÇ°í ÀÖ½À´Ï´Ù.

¹«·á ÁÖ¹®À» ¹Þ¾Æ¼­ ¸¸µå´Â ¼­ºñ½º :

ÀÌ º¸°í¼­¸¦ ±¸µ¶ÇÏ´Â °í°´Àº ´ÙÀ½ ¹«·á ¸ÂÃã¼³Á¤ ¿É¼Ç Áß Çϳª¸¦ »ç¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù.

  • ±â¾÷ ÇÁ·ÎÆÄÀÏ
    • Ãß°¡ ½ÃÀå ±â¾÷ÀÇ Á¾ÇÕÀû ÇÁ·ÎÆÄÀϸµ(3°³»ç±îÁö)
    • ÁÖ¿ä ±â¾÷ÀÇ SWOT ºÐ¼®(3°³»ç±îÁö)
  • Áö¿ª ¼¼ºÐÈ­
    • °í°´ÀÇ °ü½É¿¡ ÀÀÇÑ ÁÖ¿ä±¹ ½ÃÀå Ãß°è, ¿¹Ãø ¹× CAGR(ÁÖ : Ÿ´ç¼º È®Àο¡ µû¸§)
  • °æÀï º¥Ä¡¸¶Å·
    • Á¦Ç° Æ÷Æ®Æú¸®¿À, Áö¸®Àû Á¸Àç, Àü·«Àû Á¦ÈÞ¿¡ ±â¹ÝÇÑ ÁÖ¿ä ±â¾÷ º¥Ä¡¸¶Å·

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ¼­¹®

  • °³¿ä
  • ÀÌÇØ°ü°èÀÚ
  • Á¶»ç ¹üÀ§
  • Á¶»ç ¹æ¹ý
    • µ¥ÀÌÅÍ ¸¶ÀÌ´×
    • µ¥ÀÌÅÍ ºÐ¼®
    • µ¥ÀÌÅÍ °ËÁõ
    • Á¶»ç Á¢±Ù
  • Á¶»ç ÀÚ·á
    • 1Â÷ Á¶»ç ÀÚ·á
    • 2Â÷ Á¶»ç Á¤º¸¿ø
    • ÀüÁ¦Á¶°Ç

Á¦3Àå ½ÃÀå µ¿Ç⠺м®

  • ¼ºÀå ÃËÁø¿äÀÎ
  • ¼ºÀå ¾ïÁ¦¿äÀÎ
  • ±âȸ
  • À§Çù
  • Á¦Ç° ºÐ¼®
  • ±â¼ú ºÐ¼®
  • ÃÖÁ¾ »ç¿ëÀÚ ºÐ¼®
  • ½ÅÈï ½ÃÀå
  • COVID-19ÀÇ ¿µÇâ

Á¦4Àå Porter's Five Forces ºÐ¼®

  • °ø±Þ±â¾÷ÀÇ Çù»ó·Â
  • ±¸¸ÅÀÚÀÇ Çù»ó·Â
  • ´ëüǰÀÇ À§Çù
  • ½Å±Ô Âü°¡¾÷üÀÇ À§Çù
  • °æÀï ±â¾÷°£ °æÀï °ü°è

Á¦5Àå ¼¼°èÀÇ ³²¼º »ý½Ä ´É·Â ÃßÀû ½ÃÀå : Á¦Ç°º°

  • Áý¿¡¼­ ÇÒ ¼ö ÀÖ´Â Á¤¾× °Ë»ç ŰƮ
  • ½º¸¶Æ®Æù ±â¹Ý Á¤¾× ºÐ¼® ÀåÄ¡
  • Ä¿³ØÆ¼µå Ȩ ¾Ö³Î¶óÀÌÀú
  • È£¸£¸ó °Ë»ç ŰƮ
  • À½³¶ ¿Âµµ ¼¾¼­
  • ³²¼ºÀÇ »ý½Ä ´É·Â ÃßÀû ¾Û
  • ¾×¼¼¼­¸® ¹× ¼Ò¸ðǰ
  • ±âŸ Á¦Ç°

Á¦6Àå ¼¼°èÀÇ ³²¼º »ý½Ä ´É·Â ÃßÀû ½ÃÀå : ÀÌ¿ë »ç·Êº°

  • ÀӽŠÀü ½ºÅ©¸®´×
  • ºÒÀÓÁõ Áø´Ü ¹× ¸ð´ÏÅ͸µ
  • Á¤°ü ÀýÁ¦ ÈÄÀÇ È®ÀÎ
  • Ä¡·á ¸ð´ÏÅ͸µ
  • ¶óÀÌÇÁ½ºÅ¸ÀÏ ¹× °Ç°­ ÃÖÀûÈ­

Á¦7Àå ¼¼°èÀÇ ³²¼º »ý½Ä ´É·Â ÃßÀû ½ÃÀå : À¯Åë ä³Îº°

  • ¿Â¶óÀÎ
  • ¿ÀÇÁ¶óÀÎ ¼Ò¸Å
  • ÀÓ»óÁ¶´Þ

Á¦8Àå ¼¼°èÀÇ ³²¼º »ý½Ä ´É·Â ÃßÀû ½ÃÀå : ±â¼úº°

  • ·¡ÅÍ·² Ç÷οì
  • ¸¶ÀÌÅ©·ÎÇ÷çÀ̵ñ½º°øÇÐ
  • ½º¸¶Æ®ÆùÀÇ ±¤ÇÐ À̹Ì¡ ¹× ÄÄÇ»ÅÍ ºñÀü
  • Àü±âÈ­ÇÐ ¹ÙÀÌ¿À¼¾¼­
  • AI/ML ±â¹Ý ºÐ¼®

Á¦9Àå ¼¼°èÀÇ ³²¼º »ý½Ä ´É·Â ÃßÀû ½ÃÀå : ÃÖÁ¾ »ç¿ëÀÚº°

  • °³ÀÎ
  • ºÒÀÓ Ä¡·á Ŭ¸®´Ð°ú ü¿Ü¼öÁ¤(IVF) ¼¾ÅÍ
  • ºñ´¢±â°ú
  • ¿ø°Ý ÀÇ·á Á¦°ø¾÷ü
  • ¿¬±¸ ¹× Çмú
  • ±âŸ ÃÖÁ¾ »ç¿ëÀÚ

Á¦10Àå ¼¼°èÀÇ ³²¼º »ý½Ä ´É·Â ÃßÀû ½ÃÀå : Áö¿ªº°

  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
    • ¸ß½ÃÄÚ
  • À¯·´
    • µ¶ÀÏ
    • ¿µ±¹
    • ÀÌÅ»¸®¾Æ
    • ÇÁ¶û½º
    • ½ºÆäÀÎ
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • ÀϺ»
    • Áß±¹
    • Àεµ
    • È£ÁÖ
    • ´ºÁú·£µå
    • Çѱ¹
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ³²¹Ì
    • ¾Æ¸£ÇîÆ¼³ª
    • ºê¶óÁú
    • Ä¥·¹
    • ±âŸ ³²¹Ì
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
    • īŸ¸£
    • ³²¾ÆÇÁ¸®Ä«
    • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦11Àå ÁÖ¿ä ¹ßÀü

  • °è¾à, ÆÄÆ®³Ê½Ê, Çù¾÷ ¹× ÇÕÀÛÅõÀÚ
  • Àμö ¹× ÇÕº´
  • ½ÅÁ¦Ç° ¹ß¸Å
  • »ç¾÷ È®´ë
  • ±âŸ ÁÖ¿ä Àü·«

Á¦12Àå ±â¾÷ ÇÁ·ÎÆÄÀϸµ

  • Legacy
  • Trak Fertility
  • Ro
  • Hims & Hers Health
  • EverlyWell
  • LetsGetChecked
  • Ferring Pharmaceuticals
  • Merck KGaA
  • Bayer AG
  • Sun Pharmaceutical Industries Ltd.
  • ExSeed Health
  • Yo Home Sperm Test
  • Dadi
  • SpermCheck
  • Andros Diagnostics
AJY 25.09.26

According to Stratistics MRC, the Global Male Fertility Tracking Market is accounted for $4.48 billion in 2025 and is expected to reach $6.97 billion by 2032 growing at a CAGR of 6.51% during the forecast period. Male fertility tracking refers to the process of monitoring and analyzing various biological, lifestyle, and health factors that influence male reproductive potential. It involves tracking parameters such as sperm count, motility, morphology, testosterone levels, scrotal temperature, and lifestyle habits like diet, exercise, sleep, and stress management. Advanced digital tools, wearables, and mobile applications are increasingly used to provide real-time insights and predictive analytics. By identifying fertility patterns, potential issues, and optimal timing for conception, male fertility tracking supports couples in achieving pregnancy goals, while also helping men maintain reproductive health and detect early signs of underlying medical conditions.

Market Dynamics:

Driver:

Rising prevalence of male-factor infertility

Declining sperm health and heightened awareness are encouraging earlier diagnostic engagement. Digital tools such as mobile apps and at-home kits are emerging as accessible alternatives to lab-based testing. AI-powered semen analysis is improving diagnostic precision and user experience. Integration with broader fertility care pathways is enhancing continuity of care. These trends are positioning the market as a key enabler of proactive reproductive health.

Restraint:

Clinical skepticism and limited integration with care pathways

Concerns about accuracy and standardization hinder physician endorsement. Lack of compatibility with electronic health systems reduces clinical utility. Disjointed care pathways weaken the link between tracking and treatment. Regulatory uncertainty around digital health tools slows institutional uptake. These issues continue to restrict clinical deployment.

Opportunity:

Greater public awareness and reduced stigma

Educational initiatives and media coverage are fostering open dialogue around reproductive health. Younger users are more receptive to digital wellness tools. Collaborations between tech firms and healthcare providers are enhancing credibility and reach. Social platforms are amplifying visibility and engagement. These shifts are creating momentum for market expansion.

Threat:

Fragmented reimbursement and out-of-pocket cost burden

Diagnostic kits and digital platforms are often excluded from standard health benefits. Cost-sensitive users may delay or avoid testing due to affordability concerns. Public funding for male reproductive health remains limited. Regional disparities in reimbursement policies exacerbate access gaps. These financial constraints pose risks to inclusive market growth.

Covid-19 Impact:

The Covid-19 pandemic significantly influenced the Male Fertility Tracking Market by disrupting supply chains, delaying product launches, and limiting in-person medical consultations. Lockdowns and social distancing measures reduced access to fertility clinics, slowing adoption of related technologies. However, increased awareness of reproductive health and the growing preference for digital platforms boosted demand for fertility tracking apps and home-based solutions. The shift toward telehealth services and remote monitoring tools accelerated innovation, fostering long-term opportunities despite initial market challenges.

The at-home semen analysis kits segment is expected to be the largest during the forecast period

The at-home semen analysis kits segment is expected to account for the largest market share during the forecast period due to rising demand for discreet and user-friendly diagnostics. These kits provide real-time insights into sperm parameters without clinical visits. Integration with mobile apps enhances tracking and engagement. E-commerce availability is expanding consumer access. Preference for privacy and affordability is driving adoption. This segment will remain dominant in male fertility tracking.

The fertility clinics & IVF centers segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the fertility clinics & IVF centers segment is predicted to witness the highest growth rate owing to increased integration of digital tracking tools in assisted reproduction. Clinics are adopting connected diagnostics to personalize treatment and improve efficiency. Demand for data-driven fertility care is prompting investment in smart technologies. Partnerships between device makers and clinical networks are enhancing interoperability. Growth in IVF services and male-factor diagnoses is accelerating adoption. This segment is set for rapid expansion across global fertility care ecosystems.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share by rising awareness about reproductive health, growing adoption of digital health tools, and the presence of advanced healthcare infrastructure. Countries like the United States and Canada are witnessing increasing acceptance of at-home fertility kits, smartphone-based analyzers, and connected devices. Supportive healthcare policies and active participation of fertility clinics enhance adoption. The influence of lifestyle-related fertility issues and high penetration of telehealth platforms further strengthens the market outlook in this region.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, fuelled by a combination of cultural shifts, increasing healthcare digitalization, and rising focus on family planning. Countries such as China, India, Japan, South Korea, and Australia are witnessing a growing adoption of affordable fertility tracking devices and mobile applications. The region is characterized by heightened awareness campaigns and government initiatives supporting reproductive health. Rapid urbanization, rising disposable incomes, and greater smartphone penetration contribute significantly to market growth, making Asia Pacific a dynamic hub for innovation.

Key players in the market

Some of the key players in Male Fertility Tracking Market include Legacy, Trak Fertility, Ro, Hims & Hers Health, EverlyWell, LetsGetChecked, Ferring Pharmaceuticals, Merck KGaA, Bayer AG, Sun Pharmaceutical Industries Ltd., ExSeed Health, Yo Home Sperm Test, Dadi, SpermCheck and Andros Diagnostics.

Key Developments:

In March 2025, Trak Fertility expanded its clinical outreach by partnering with Labcorp to integrate Trak's at-home sperm testing data into Labcorp's digital health ecosystem. This collaboration enhances continuity of care by linking Trak's consumer diagnostics with physician-ordered fertility evaluations and treatment pathways.

In October 2024, Legacy partnered with Posterity Health to deliver integrated male fertility care through a hybrid model combining at-home sperm testing and virtual specialist consultations. The collaboration expands access to semen analysis, DNA fragmentation testing, and hormone care, streamlining diagnostics and treatment for men nationwide.

Products Covered:

  • At-home semen analysis kits
  • Smartphone-based semen analyzers
  • Connected home analyzers
  • Hormone test kits
  • Scrotal temperature sensors
  • Male fertility tracking apps
  • Accessories & consumables
  • Other Products

Use Cases Covered:

  • Pre-conception screening
  • Infertility diagnosis & monitoring
  • Post-vasectomy confirmation
  • Treatment monitoring
  • Lifestyle & wellness optimization

Distribution Channels Covered:

  • Online
  • Offline retail
  • Clinical procurement

Technologies Covered:

  • Lateral flow
  • Microfluidics
  • Smartphone optical imaging & computer vision
  • Electrochemical biosensors
  • AI/ML-based analytics

End Users Covered:

  • Individuals
  • Fertility clinics & IVF centers
  • Urology
  • Telehealth providers
  • Research & academia
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Technology Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Male Fertility Tracking Market, By Product

  • 5.1 Introduction
  • 5.2 At-home semen analysis kits
  • 5.3 Smartphone-based semen analyzers
  • 5.4 Connected home analyzers
  • 5.5 Hormone test kits
  • 5.6 Scrotal temperature sensors
  • 5.7 Male fertility tracking apps
  • 5.8 Accessories & consumables
  • 5.9 Other Products

6 Global Male Fertility Tracking Market, By Use Case

  • 6.1 Introduction
  • 6.2 Pre-conception screening
  • 6.3 Infertility diagnosis & monitoring
  • 6.4 Post-vasectomy confirmation
  • 6.5 Treatment monitoring
  • 6.6 Lifestyle & wellness optimization

7 Global Male Fertility Tracking Market, By Distribution Channel

  • 7.1 Introduction
  • 7.2 Online
  • 7.3 Offline retail
  • 7.4 Clinical procurement

8 Global Male Fertility Tracking Market, By Technology

  • 8.1 Introduction
  • 8.2 Lateral flow
  • 8.3 Microfluidics
  • 8.4 Smartphone optical imaging & computer vision
  • 8.5 Electrochemical biosensors
  • 8.6 AI/ML-based analytics

9 Global Male Fertility Tracking Market, By End User

  • 9.1 Introduction
  • 9.2 Individuals
  • 9.3 Fertility clinics & IVF centers
  • 9.4 Urology
  • 9.5 Telehealth providers
  • 9.6 Research & academia
  • 9.7 Other End Users

10 Global Male Fertility Tracking Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Legacy
  • 12.2 Trak Fertility
  • 12.3 Ro
  • 12.4 Hims & Hers Health
  • 12.5 EverlyWell
  • 12.6 LetsGetChecked
  • 12.7 Ferring Pharmaceuticals
  • 12.8 Merck KGaA
  • 12.9 Bayer AG
  • 12.10 Sun Pharmaceutical Industries Ltd.
  • 12.11 ExSeed Health
  • 12.12 Yo Home Sperm Test
  • 12.13 Dadi
  • 12.14 SpermCheck
  • 12.15 Andros Diagnostics
»ùÇà ¿äû ¸ñ·Ï
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
¸ñ·Ï º¸±â
Àüü»èÁ¦